gemcitabine / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

130 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
NCT02992015: Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

Active, not recruiting
1
2
US
Gemcitabine, Gemzar
University of Colorado, Denver, Children's Hospital Colorado
Diffuse Intrinsic Pontine Glioma
02/18
12/25
NCT05182112: Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer With Homologous Recombination Deficiency That Has Spread to the Liver

Active, not recruiting
1
1
US
Whole liver irradiation (WLI), Gemcitabine and Cisplatin
Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
12/24
12/24
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting
1
60
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
ChiCTR2200063680: An exploratory clinical study on the efficacy and safety of tirelizumab combined with gemcitabine and albumin paclitaxel in the treatment of borderline resectable pancreatic cancer

Not yet recruiting
1
30
 
Treatment programs
The Second Affiliated Hospital of the Army Medical University;, Self raised funds
Pancreatic cancer
 
 
TASUC-Neo, NCT05839119: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

Recruiting
1
32
US
Degarelix, Firmagon Kit, Gemcitabine/Cisplatin
Brown University, Legorreta Cancer Center at Brown University, Lifespan, Cures Within Reach
Urothelial Carcinoma Bladder, Androgen Receptor Positive
01/25
01/30
NCT05497778: A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Recruiting
1
25
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab paclitaxel, Paclitaxel (protein-bound), Abraxane, ABI-007, IM156
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Pancreas Cancer
01/25
01/25
NCT04088188: Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Terminated
1
8
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Ivosidenib, AG-120, Tibsovo, Pemigatinib, INCB054828, Pemazyre
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma
12/23
12/23
NCT05984602: A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Recruiting
1
10
US
Canakinumab, ACZ885, Tislelizumab, Nab-Paclitaxel, Gemcitabine
NYU Langone Health
Pancreatic Cancer
02/25
06/25
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26
MK-0482-001, NCT03918278: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Active, not recruiting
1
230
Europe, Canada, US, RoW
MK-0482, pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin ®, Pemetrexed, Alimta
Merck Sharp & Dohme LLC
Neoplasms
02/25
02/25
NCT05685602: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Suspended
1
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Emavusertib, AU 4948, AU-4948, CA 4948, CA-4948, CA4948, Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948, IRAK4 Inhibitor CA-4948, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
03/25
03/25
NCT03432741: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Suspended
1
39
US
Belinostat, Beleodaq, PXD 101, PXD101, Carfilzomib, Kyprolis, PR-171, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
Mayo Clinic, National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
04/25
05/26
NCT04877587: Gemcitabine With Ascorbate Including Adolescents

Withdrawn
1
20
US
Ascorbate, Vitamin C, Gemcitabine, Gemzar®
David Dickens
Soft Tissue Sarcoma, Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Soft-tissue Sarcoma, Unresectable Bone Sarcoma
05/25
05/25
NCT06076837: The Seven Trial: Exploiting the Unfolded Protein Response

Not yet recruiting
1
12
US
Botensilimab, AGEN1811, Balstilimab, AGEN2034, Chloroquine Phosphate, Aralen, Celecoxib, Celebrex
HonorHealth Research Institute, Translational Genomics Research Institute, University of Arizona, Agenus Inc.
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
06/25
12/25
ChiCTR2300067932: A single-center prospective phase II clinical study of Sindillimab combined with anrotinib and gemcitabine in the treatment of potentially resectable bile duct carcinoma

Recruiting
1
20
 
Sindillimab in combination with androtinib and gemcitabine
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Investigator initiated (self-funded)
cholangiocarcinoma
 
 
NCT05141643: Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

Recruiting
1
30
US
PET Scan, 18F-FAC PET Scan
Memorial Sloan Kettering Cancer Center
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
11/25
11/25
NCT03093909: Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Recruiting
1
44
US
Gemcitabine, GCB, aerosol gemcitabine, Aerosolized GCB
M.D. Anderson Cancer Center, James B. and Lois R. Archer Charitable Foundation, Gateway for Cancer Research
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasm of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract, Melanoma and Other Malignant Neoplasms of Skin
11/25
11/25
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
120
Europe, Japan, US, RoW
RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Genentech, Inc., Chugai Pharmaceutical Co.
Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
12/25
12/25
NeoTGP01, NCT04947241: Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Recruiting
1
20
RoW
PD-1 inhibitor+ Gemcitabine + Cisplatin, Toripalimab
Fifth Affiliated Hospital, Sun Yat-Sen University
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
01/26
01/26
NCT04158635: Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Recruiting
1
21
US
Bosentan, Bosentan Monohydrate, Ro 47-0203, Tracleer, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
01/26
01/26
PARPAML, NCT05101551: Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Recruiting
1
34
US
Talazoparib, Talzenna, Topotecan, Hycamtin, Gemcitabine, Gemzar, Infugem
Jennifer Lauren Kamens, Gateway for Cancer Research
Acute Myeloid Leukemia
03/26
03/26
ProglumidePanc, NCT06017323: Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

Withdrawn
1
12
US
Gemcitabine, Gemzar, Nab paclitaxel, Proglumide Dose level 1, Proglumide Dose level 2
Georgetown University
Metastatic Pancreatic Cancer
07/26
07/26
ADCT-601-102, NCT05389462: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Recruiting
1
260
Europe, US
ADCT-601, Mipasetamab uzoptirine, Gemcitabine
ADC Therapeutics S.A.
Advanced Solid Tumors
08/26
08/27
NCT05325281: CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Recruiting
1
24
US
CPI-613® (Dose level -1.0 250 mg/m^2), Devimistat, alpha-lipoic acid analogue CPI-613, CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Gemzar®, Intensity-modulated Radiation Therapy
Medical College of Wisconsin, Cornerstone Pharmaceuticals, Barbara Ann Karmanos Cancer Institute
Pancreas Adenocarcinoma
08/26
08/27
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Recruiting
1
430
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
NCT05006794: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Recruiting
1
195
US, RoW
GS-9716, Docetaxel, sacituzumab govitecan-hziy
Gilead Sciences
Solid Malignancies
01/27
01/27
ChiCTR2300075094: PD-1 inhibitor and nimotuzumab plus induction chemotherapy, concurrent therapy, in combination with capecitabine as adjuvant therapy, for T3-4N3M0 nasopharyngeal carcinoma: a single arm, phase II clinical trial

Recruiting
1
29
 
Stage of induction traetment: 3 cycles of PD-1 inhibitor (200mg，d0，q3w) plus nimotuzumab (100mg，d0、d8，q3w) and chemotherapy (gemcitabine, 1000 mg/m2，d1、d8; cisplatin, 80mg/m2， d1，q3w), 21 days is a cycle. Stage of Concurrent treatment: cisplatin, 80mg/m2，d1，q3w, 2cycles; nimotuzumab 200mg，d1，qw; radiotherapy for nasopharynx and cervical metastatic lymph node. Stage of adjuvant treatment: Capecitabine (650mg/m2, take orally, two times every day) until 1 year or the end of the study.
The Tenth Affiliated Hospital of Southern Medical University (Dongguan people's hospital); The Tenth Affiliated Hospital of Southern Medical University (Dongguan people's hospital), Biotech Pharmaceutical Co., Ltd
nasopharyngeal carcinoma
 
 
NCT03233139: Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Checkmark From trial for advanced malignancies in Japanese patients at ASCO-SITC 2019 [screenshot]
Mar 2019 - Mar 2019: From trial for advanced malignancies in Japanese patients at ASCO-SITC 2019 [screenshot]
Recruiting
1
145
Japan
Cemiplimab, REGN2810, Libtayo, Ipilimumab, Platinum-doublet chemotherapy, Gemcitabine, Gemzar, Pemetrexed, Alimta, Paclitaxel, Taxol, Fianlimab
Regeneron Pharmaceuticals
Advanced Malignancies
12/27
03/30
MACOCUC-01, NCT05738161: Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma

Recruiting
1
26
Europe
Magrolimab, Hu-5F9-G4, Cisplatin, L01XA01 Cisplatin, Gemcitabine, L01BC05 Gemcitabine
Insel Gruppe AG, University Hospital Bern, University of Bern, Swiss National Science Foundation
Advanced Urothelial Carcinoma
08/28
08/28
NCT05919537: Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Recruiting
1
68
RoW
HMBD-001, Docetaxel, Nab-paclitaxel, Gemcitabine
Hummingbird Bioscience
Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/31
03/31
 

Download Options